Drug maker Glenmark Generics today said it has received United States Food and Drug Administration approval for marketing and distribution of Betamethasone Dipropionate Cream, used in the treatment of inflammatory diseases.
Betamethasone is used in the treatment of inflammatory diseases and is the generic therapeutic equivalent of Diprolene cream marketed by Schering.
The medicine would be manufactured at Glenmark's US FDA approved factory located in Baddi, the company said in a filing to the Bombay Stock Exchange.
The company will soon start marketing and distributing the product in the US market.
It had earlier licensed the US marketing rights for a line of dermatology products that include - cream, emulsified cream, ointment, gel and topical solution through a US-based pharmaceutical development company.
Glenmark's current portfolio consists of 34 products, authorised for distribution in the US market place. The company has over 35 pending approval with the US FDA of which 20 per cent fall within the dermatology segment.
Shares of the company were trading at Rs 594.95, up 2.11 per cent in afternoon trade on the BSE.
